These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17136236)

  • 21. Antiplatelet therapy: anti-ischemic benefits versus bleeding risk.
    Gibson CM
    J Interv Cardiol; 2008 Dec; 21 Suppl 1():S3-9. PubMed ID: 19090934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
    Testa L; Zoccai GB; Porto I; Trotta G; Agostoni P; Andreotti F; Crea F
    Am J Cardiol; 2007 Jun; 99(12):1637-42. PubMed ID: 17560866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombocytopenia associated with antithrombotic therapy in acute coronary syndrome.
    Ho R; Kayser SR
    Prog Cardiovasc Nurs; 2003; 18(4):198-200. PubMed ID: 14605523
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombocytopenia following percutaneous coronary intervention.
    Shenoy C; Harjai KJ
    J Interv Cardiol; 2011 Feb; 24(1):15-26. PubMed ID: 20040007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraoperative antiaggregant strategy for off-pump coronary artery bypass grafting in a patient with heparin-induced thrombocytopenia.
    Zanobini M; Barili F; Alamanni F; Dainese L; Stringi V; Cappai A; Dell'orto M; Porqueddu M; Roberto M; Kassem S; Pompilio G; Biglioli P
    Heart Surg Forum; 2008; 11(1):E54-5. PubMed ID: 18270143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bleeding is bad.... isn't it?
    Berger PB; Manoukian SV
    Circulation; 2007 Dec; 116(24):2776-8. PubMed ID: 18071086
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.
    Crespo EM; Oliveira GB; Honeycutt EF; Becker RC; Berger PB; Moliterno DJ; Anstrom KJ; Abrams CS; Kleiman NS; Moll S; Rice L; Rodgers JE; Steinhubl SR; Tapson VF; Granger CB; Ohman EM;
    Am Heart J; 2009 Apr; 157(4):651-7. PubMed ID: 19332191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulants in coronary artery disease.
    Lee LV
    Cardiol Clin; 2008 Nov; 26(4):615-28. PubMed ID: 18929235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anesthetic implications of the new anticoagulant and antiplatelet drugs.
    Vitin AA; Dembo G; Vater Y; Martay K; Azamfirei L; Ezri T
    J Clin Anesth; 2008 May; 20(3):228-37. PubMed ID: 18502371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of thrombocytopenia in the acute coronary syndrome.
    Matthai WH
    Curr Opin Hematol; 2010 Sep; 17(5):398-404. PubMed ID: 20703115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balancing myocardial ischemic and bleeding risks in patients with non-ST-segment elevation myocardial infarction.
    Díez JG; Cohen M
    Am J Cardiol; 2009 May; 103(10):1396-402. PubMed ID: 19427435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes.
    Potsis TZ; Katsouras C; Goudevenos JA
    Angiology; 2009; 60(2):148-58. PubMed ID: 18508853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and features of heparin-induced thrombocytopenia (HIT) in burn patients: a retrospective study.
    Hejl CG; Leclerc T; Bargues L; Samson T; Foissaud V
    Thromb Haemost; 2008 May; 99(5):974-6. PubMed ID: 18449436
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    Rossini R; Musumeci G; Lettieri C; Molfese M; Mihalcsik L; Mantovani P; Sirbu V; Bass TA; Della Rovere F; Gavazzi A; Angiolillo DJ
    Am J Cardiol; 2008 Dec; 102(12):1618-23. PubMed ID: 19064015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
    Nguyen MC; Lim YL; Walton A; Lefkovits J; Agnelli G; Goodman SG; Budaj A; Gulba DC; Allegrone J; Brieger D;
    Eur Heart J; 2007 Jul; 28(14):1717-22. PubMed ID: 17562671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there less benefit from warfarin in diabetics after myocardial infarction? The numbing complexities of assessing anticoagulant and antiplatelet therapy in the diabetic patient.
    Smith DA
    Cardiology; 2008; 111(3):158-60. PubMed ID: 18434718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.